(UroToday.com) Upfront cytoreductive nephrectomy is no longer recommended in patients treated with tyrosine kinase inhibitors since the CARMENA trial.1 Response of the primary tumor in mRCC has been described in the TKI era but remains unknown with immune checkpoint inhibitors. At the ESMO 2020 virtual annual meeting, Dr. Jean Courcier and colleagues presented results of their study describing the response of the primary tumor in patients who did not undergo cytoreductive nephrectomy and received nivolumab within the GETUG-AFU-26 NIVOREN study.